Sales Performance - Q3 2025 total sales reached $197.1 million, a 10.1% increase compared to Q3 2024, with comparable store sales growth of 10.8%[6] - Year-to-date total sales of $589.6 million, reflecting an 8.8% increase versus 2024, with comparable store sales growth of 10.0%[11] - Net sales for Q3 2025 were $197,091,000, an increase of 10.3% compared to $179,066,000 in Q3 2024[16] Financial Metrics - Gross margin for Q3 2025 was 38.9%, a decline of 90 basis points compared to Q3 2024[6] - SG&A expenses for Q3 2025 were $79.3 million, up from $74.7 million in Q3 2024, reflecting higher sales processing costs[6] - Net loss for Q3 2025 was $6.9 million, compared to a net loss of $7.2 million in Q3 2024[6] - Adjusted net loss for Q3 2025 was $7,089,000, compared to an adjusted net loss of $6,524,000 in Q3 2024[21] - Adjusted EBITDA loss improved to $2.9 million in Q3 2025 from a loss of $3.3 million in Q3 2024[11] - Adjusted EBITDA for Q3 2025 was $(2,912,000), an improvement from $(3,332,000) in Q3 2024[21] Future Projections - The company expects full-year EBITDA to be in the range of $10 million to $12 million, representing a $24 million to $26 million improvement compared to 2024[11] - For Q4 2025, comparable store sales are expected to increase by high-single digits, with gross margin projected between 40% and 41%[11] - The company has set a target of achieving approximately $45 million in EBITDA by fiscal 2027, a $60 million improvement from 2024 levels[5] Asset and Liability Changes - Total assets decreased to $464,260,000 in Q3 2025 from $467,076,000 in Q3 2024[18] - Total liabilities increased to $356,430,000 in Q3 2025 from $336,806,000 in Q3 2024[18] - Cash and cash equivalents rose to $51,098,000 in Q3 2025, up from $38,872,000 in Q3 2024[18] - Inventory decreased to $123,536,000 in Q3 2025 from $127,514,000 in Q3 2024[18] Store Operations - The company plans to open 3 new stores and remodel 62 stores in fiscal 2025, while closing 4 locations[11] - The company reported a gain on the sale of a building amounting to $10,960,000 during the thirty-nine weeks ended November 1, 2025[22]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 1, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-41249 Credo Technology Group Holding Ltd (Exact name of registrant as specified in its charter) Cayman ...

Financial Performance - Fourth quarter 2025 revenue totaled $712 million, an increase of $27.7 million or 4.1% year over year, primarily due to an additional week of operations[9] - Operating income for the fourth quarter was $17.6 million, down from $29.8 million in the same quarter of 2024, a decrease of $12.2 million[10] - The company reported a net loss of $13 million, or $(0.10) per diluted share, while adjusted net income was $4 million, or $0.03 per diluted share[7] - Revenue for the three months ended October 3, 2025, was $712,011 thousand, an increase from $684,281 thousand for the same period in 2024, representing a growth of approximately 3.3%[31] - Operating income decreased to $17,641 thousand for the three months ended October 3, 2025, compared to $29,776 thousand for the same period in 2024, a decline of about 40.7%[31] - Net loss for the three months ended October 3, 2025, was $12,549 thousand, compared to a net loss of $2,298 thousand for the same period in 2024, indicating a significant increase in losses[31] - Adjusted EBITDA for the fiscal year ended October 3, 2025, was $257,425 thousand, down from $352,900 thousand in the previous year, representing a decrease of approximately 27%[37] - Free Cash Flow for the three months ended October 3, 2025, was $15,569 thousand, significantly lower than $267,470 thousand for the same period in 2024[40] - Adjusted Net Income for the fiscal year ended October 3, 2025, was $32,484 thousand, down from $82,266 thousand in the previous year[39] Cash Flow and Liquidity - Cash flows provided by operating activities for the fourth quarter were $31 million, with free cash flow of $16 million[7] - Total cash and excess availability under the revolving credit facility was $298 million as of October 3, 2025, down from $326 million a year earlier[15] - Cash and cash equivalents at the end of the period were $29,748 thousand, a decrease from $31,010 thousand at the end of the previous fiscal year[35] - The company reported a net cash provided by operating activities of $30,927 thousand for the three months ended October 3, 2025, compared to $295,588 thousand for the same period in 2024, a decrease of approximately 89.6%[35] - Free cash flow for fiscal 2026 is anticipated to be in the range of $50 million to $60 million[16] Strategic Initiatives - The strategic business transformation plan aims to generate annual operating cost savings of at least $75 million by the end of fiscal 2026[5] - The strategic plan focuses on three pillars: Commercial Excellence, Operational Excellence, and Asset & Network Optimization[6] Debt and Liabilities - Total current assets as of October 3, 2025, were $850,031 thousand, up from $813,269 thousand as of September 27, 2024, reflecting an increase of approximately 4.5%[33] - Total liabilities increased to $2,041,256 thousand as of October 3, 2025, compared to $2,029,336 thousand as of September 27, 2024, showing a rise of about 0.6%[33] - Total principal debt outstanding as of October 3, 2025, was $1,168,500 thousand, slightly up from $1,162,500 thousand as of September 27, 2024[40] - The Net Leverage Ratio as of October 3, 2025, increased to 4.72 from 3.64 in the previous year, indicating a higher level of debt relative to EBITDA[40] Expenses and Charges - Interest expense for the three months ended October 3, 2025, was $24,343 thousand, down from $29,848 thousand for the same period in 2024, a reduction of about 18.5%[31] - The company incurred $6,309 thousand in severance and other related charges for the three months ended October 3, 2025, compared to $3,741 thousand in the same period of 2024[39] - Share-based compensation expenses for the fiscal year ended October 3, 2025, totaled $11,565 thousand, down from $16,336 thousand in the previous year[39] Forward-Looking Statements - Fiscal 2026 revenue is expected to be flat to down 2% compared to normalized fiscal 2025 revenue, with adjusted EBITDA projected between $285 million and $315 million[16] - The company expects to provide forward-looking non-GAAP financial information, including expected Adjusted EBITDA and Free Cash Flow for 2026, but cannot provide a quantitative reconciliation to GAAP measures without unreasonable efforts[28]

Financial Results Announcement - NewtekOne, Inc. announced its financial results for the three and nine months ended September 30, 2025[7]. - The press release detailing the financial results was issued on October 29, 2025[7]. - The financial results are available on NewtekOne's investor relations website and the SEC's website[6]. Company Information - The company is registered under the Securities Exchange Act of 1934 and has various securities listed on the Nasdaq Global Market[3]. - The company operates from Boca Raton, Florida, and is incorporated in Maryland[2]. Forward-Looking Statements and Risks - NewtekOne's forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially[6]. - The report includes a note regarding forward-looking statements and risk factors associated with the company's operations[6]. Compliance and Reporting - The company has not elected to use the extended transition period for complying with new financial accounting standards[5]. - The report was signed by Barry Sloane, the Chief Executive Officer, President, and Chairman of the Board[13]. - The report does not include specific financial metrics or performance indicators[8].

Revenue and Financial Performance - The software business accounted for 58% of total revenue for the fiscal year ended August 31, 2025[33]. - The services business represented 42% of total revenue for the fiscal year ended August 31, 2025, an increase from 39% in 2023[47]. - Software revenue accounted for 58% of total revenue in fiscal year 2025, down from 61% in 2023[52]. - Revenue increased by $9.2 million, or 13%, to $79.2 million for the fiscal year ended August 31, 2025, compared to $70.0 million for the fiscal year ended August 31, 2024[206]. - Cost of revenues increased by $6.1 million, or 23%, primarily due to a $3.2 million or 49% increase in software-related costs and a $2.9 million or 14% increase in service-related costs[207]. - Gross profit increased by $3.1 million, or 7%, to $46.2 million, with gross margin percentages of 58% for 2025 and 62% for 2024, indicating a decline in gross margin[208]. - The company reported a net loss of $64.7 million for the fiscal year ended August 31, 2025, compared to a net income of $9.9 million for the fiscal year ended August 31, 2024, representing a decline of 750%[205]. - The company incurred $77.2 million in impairments for the fiscal year ended August 31, 2025, which significantly impacted overall financial performance[205]. - Other income decreased by $4.9 million, or 78%, to $1.4 million for the fiscal year ended August 31, 2025, compared to $6.3 million for the fiscal year ended August 31, 2024[205]. Product Development and Innovation - Version 13 of ADMET Predictor was released in June 2025, introducing new features including OBESITYsym™ and Thales™[35]. - GastroPlus version 10 (branded as GPX™) was released in May 2024, featuring a redesigned platform with advanced models and integrated ML technology[38]. - The ADMET Predictor software predicts over 175 different properties for molecular structures, enhancing drug discovery efficiency[33]. - The company has made significant investments in improving integration of its software models and enhancing its AI/ML engine[37]. - The company supports clients in drug development from early discovery through clinical trials to commercialization[23]. - The company aims to derive more revenues from existing clients by expanding their use of products and services[100]. Strategic Initiatives and Collaborations - The company has entered collaborations for validation of ADMET Predictor models and development of new AI drug discovery offerings[39]. - The company pivoted to an account-based solution selling business model during Q4 2025, focusing on client pain points across the drug development lifecycle[55]. - The company is actively seeking strategic acquisitions to expand its pharmaceutical software portfolio and services offerings[60]. - The company has developed products internally and intends to continue licensing or acquiring technology from third parties when it makes business sense[64]. Employee Engagement and Corporate Culture - The company employed 213 people as of August 31, 2025, with over 70% having backgrounds in life sciences software, services, and R&D[71]. - The voluntary turnover rate was under 6% in fiscal year 2024, indicating strong employee engagement[72]. - The company plans to place greater emphasis on leadership development and succession planning in the coming year[76]. - The company maintains a remote-first philosophy to support employee work-life balance[89]. - The company has a paid parental leave program and increased focus on physical and mental wellness for employees[92]. Risks and Challenges - The company faces risks from increasing competition and costs in the pharmaceutical and biotechnology industries[102]. - The life science market for modeling and simulation software is highly competitive, with significant pressure from larger technology companies and open-source alternatives[105]. - The lengthy sales cycle may lead to delays in recognizing revenue, negatively impacting financial results if contracts are not finalized[110]. - Fixed-price contracts pose financial risks, including potential losses from underpricing or overrunning cost estimates[111]. - The company faces risks associated with global operations, including currency fluctuations and political instability, which could adversely affect financial results[114]. - Changes in U.S. and international tax laws could negatively impact the company's effective tax rate and overall financial results[115]. - The company is dependent on key personnel, and the loss of these employees could harm business operations[122]. - Acquisitions and strategic alliances carry risks, including integration challenges and potential undiscovered liabilities[123]. - The company faces foreign currency exchange rate risks due to international operations, which could materially affect revenues and profit margins[126]. - The reliance on a single internal hosting facility and Amazon Web Services for operations poses risks; disruptions could adversely impact business[139]. Compliance and Governance - The company is committed to strong corporate governance practices, with a diverse Board of Directors overseeing risk management[94]. - The company emphasizes the importance of data security and compliance with various data privacy laws, including the EU GDPR and China's PIPL[92]. - The company has implemented a comprehensive data privacy management program to comply with evolving data privacy laws globally[138]. - Changes in data privacy laws could impose additional compliance costs and operational complexities for the company[136]. - The company has established a comprehensive cybersecurity program to address risks and ensure compliance with legal obligations, guided by industry best practices[174]. - As of the report date, there are no known cybersecurity incidents that have materially impacted the company's financial condition[177]. Financial Management and Shareholder Value - The company has suspended quarterly dividends on common stock to reinvest in the business, with no expectation of future dividends[157]. - The company has authorized a share repurchase program of up to $50 million, with $20 million already repurchased as of May 31, 2023[165]. - The company may need to raise additional capital, which could dilute existing shareholders and impact stock price[163]. - The company's stock price may be volatile due to various factors, including market conditions and operational performance[160]. - The company’s ability to maintain effective internal controls over financial reporting may be challenged as it grows through acquisitions[156].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended AUGUST 31, 2025 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from _________ to _________________ Commission File Number: 000-19954 JEWETT-CAMERON TRADING CO LTD (Name of registrant as specified in its charter) British Columbia, CanadaA1 00-00 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended AUGUST 31, 2025 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from _________ to _________________ Commission File Number: 000-19954 JEWETT-CAMERON TRADING CO LTD (Name of registrant as specified in its charter) British Columbia, CanadaA1 00-00 ...

Revenue Segments - The A&D segment accounted for approximately 44% of total revenue from continuing operations in 2025, up from 34% in 2023[21] - The USG segment represented about 35% of total revenue from continuing operations in 2025, down from 40% in 2024 and 2023[24] - The Test segment contributed approximately 21% of total revenue from continuing operations in 2025, a decrease from 26% in 2023[27] - Direct and indirect sales to the U.S. Government accounted for approximately 23% of total revenue from continuing operations in 2025, up from 17% in 2023[32] - The company’s international sales accounted for approximately 34% of total revenue from continuing operations in 2025[31] - Approximately 23% of the company's revenues from continuing operations in 2025 were generated from sales to the U.S. Government or its contractors, primarily within the A&D segment[66] Backlog and Orders - Total Company backlog of firm orders at September 30, 2025, was $1,133.6 million, an increase of 70.7% from $664.2 million at September 30, 2024[40] - The company's twelve-month backlog as of September 30, 2025, was approximately $722 million, representing confirmed orders expected to be recognized as revenue within the next twelve months[68] - Entered orders for 2025 totaled $1,564.8 million, resulting in a book-to-bill ratio of 1.43x, with backlog increasing by 70.7% to $1,133.6 million[132][135] Acquisitions and Investments - In April 2025, the company acquired the Signature Management & Power business, enhancing its capabilities in naval defense solutions[19] - The company acquired MPE Limited in November 2023, a manufacturer of high-performance products for critical infrastructure applications[19] - The company completed the acquisition of ESCO Maritime Solutions for approximately $472 million on April 25, 2025, contributing to revenue growth[132] - The company completed the sale of its former A&D subsidiary VACCO Industries for net sales proceeds of approximately $270 million in July 2025, reflecting a strategic portfolio analysis aimed at high-growth markets[152] Financial Performance - Sales for 2025 were $1,095.4 million, a 19.2% increase from $919.1 million in 2024, with net earnings from continuing operations rising to $116.3 million from $102.6 million[127] - Diluted EPS – GAAP from continuing operations increased by 13.1% to $4.49 in 2025, compared to $3.97 in 2024[127] - EBIT from continuing operations increased to $170.4 million in 2025, a 16.6% rise from $146.2 million in 2024, with significant contributions from all segments[141] - Net cash provided by operating activities from continuing operations increased to $200.4 million in 2025 from $121.6 million in 2024, driven by higher net earnings and lower working capital requirements[156] Operational Efficiency - The company is focused on reducing operating costs and enhancing product branding through the ESCO Operating System initiative, which began in 2025[19] - Selling, general and administrative expenses were $234.6 million, or 21.4% of net sales, compared to 22.7% in 2024, reflecting improved efficiency[137] - The company incurred capital expenditures of $36.3 million in 2025, up from $28.3 million in 2024, with increases across all three business segments[157] Workforce and Culture - As of September 30, 2025, the company employed 3,425 individuals, with 3,359 being full-time employees, and 28% located in 16 offices outside the USA[48] - The average tenure of the company's workforce was 9 years, with one-third of employees having been with the company for 10 or more years[55] - The company conducted a global engagement survey with a response rate of 74%, showing an overall global engagement increase to 83%[52] - The company has launched the Leadership Education and Development Program (LEAD) to foster professional growth, with an inaugural cohort of ten participants starting in April 2025[54] Compliance and Risks - The company faces significant compliance costs and reputational risks due to complex U.S. and foreign government regulations affecting international sales[76] - Environmental laws and regulations could increase compliance costs and adversely affect profitability, with potential fines for non-compliance[90] - Cybersecurity threats pose risks to the company's information technology systems, potentially affecting business operations and incurring significant costs[80] - The company is exposed to product liability risks, which could result in costly fixes and litigation if defects are found in products[87] Financial Controls and Governance - The company maintained effective internal control over financial reporting as of September 30, 2025, based on criteria established in the Internal Control – Integrated Framework[183] - The internal control over financial reporting has been audited by Grant Thornton, an independent registered public accounting firm, as of September 30, 2025[185] - The Company has adopted an Insider Trading Policy to prevent trading in Company securities while in possession of material non-public information[191] Stock and Shareholder Information - As of November 14, 2025, there were approximately 1,894 holders of record of the company's common stock[110] - The company's common stock is listed on the New York Stock Exchange under the trading symbol "ESE"[110] - The company did not repurchase any shares during the fourth quarter of 2025[111] - The cumulative total shareholder return for the company was $266.11 as of September 30, 2025, compared to $100 at the start of the measurement period on September 30, 2020[117]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 KESTRA MEDICAL TECHNOLOGIES, LTD. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 3933 Lake Washington Blvd NE Suite 200 Kirkland, Washington 98033 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) ...

Exhibit 99.1 HAFNIA QUARTERLY-FINANCIAL-INFORMATION-Q3-2025 The product tanker market was counter-cyclically firm throughout the third quarter, driven by continued growth in clean petroleum products exports, especially from the Middle East. This market strength carried in the fourth quarter, further supported by improved refining margins and the ongoing impact of sanctions, which are still causing inefficiencies and disruptions in trading routes. I am pleased to announce that Hafnia delivered strong earning ...